Wealth Enhancement Trust Services’s Aurinia Pharmaceuticals AUPH Stock Holding History

Wealth Enhancement Trust Services’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85	Buy	+5	New	+$80	﹤0.01%	1423

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

HIM

Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

RWM

Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return

Wealth Enhancement Trust Services's AUPH Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 5 shares worth $85. The stake represents ﹤0.01% of the portfolio and ranks #1423 among its holdings.

165 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Wealth Enhancement Trust Services held 5 shares of Aurinia Pharmaceuticals worth $85 as of Q2 2026.
Aurinia Pharmaceuticals was a new Wealth Enhancement Trust Services position in Q2 2026.
Aurinia Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1423 holding.
165 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.